Identification and analysis of promiscuity cliffs formed by bioactive compounds and experimental implications
暂无分享,去创建一个
[1] George Papadatos,et al. The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..
[2] J. Bajorath,et al. Polypharmacology: challenges and opportunities in drug discovery. , 2014, Journal of medicinal chemistry.
[3] Ian A. Watson,et al. Rules for identifying potentially reactive or promiscuous compounds. , 2012, Journal of medicinal chemistry.
[4] Jürgen Bajorath,et al. Quantifying the Tendency of Therapeutic Target Proteins to Bind Promiscuous or Selective Compounds , 2015, PloS one.
[5] R. Solé,et al. Data completeness—the Achilles heel of drug-target networks , 2008, Nature Biotechnology.
[6] John J. Irwin,et al. ZINC 15 – Ligand Discovery for Everyone , 2015, J. Chem. Inf. Model..
[7] B. Shoichet,et al. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.
[8] Evan Bolton,et al. PubChem's BioAssay Database , 2011, Nucleic Acids Res..
[9] José L. Medina-Franco,et al. Data Mining of Protein-Binding Profiling Data Identifies Structural Modifications that Distinguish Selective and Promiscuous Compounds , 2012, J. Chem. Inf. Model..
[10] Janet M Thornton,et al. On the diversity of physicochemical environments experienced by identical ligands in binding pockets of unrelated proteins , 2010, Proteins.
[11] Daniel J. Warner,et al. Matched molecular pairs as a medicinal chemistry tool. , 2011, Journal of medicinal chemistry.
[12] Jürgen Bajorath,et al. Matched molecular pair analysis of small molecule microarray data identifies promiscuity cliffs and reveals molecular origins of extreme compound promiscuity. , 2012, Journal of medicinal chemistry.
[13] Jameed Hussain,et al. Computationally Efficient Algorithm to Identify Matched Molecular Pairs (MMPs) in Large Data Sets , 2010, J. Chem. Inf. Model..
[14] Jürgen Bajorath,et al. MMP-Cliffs: Systematic Identification of Activity Cliffs on the Basis of Matched Molecular Pairs , 2012, J. Chem. Inf. Model..
[15] Jürgen Bajorath,et al. Influence of Search Parameters and Criteria on Compound Selection, Promiscuity, and Pan Assay Interference Characteristics , 2014, J. Chem. Inf. Model..
[16] Jürgen Bajorath,et al. Highly Promiscuous Small Molecules from Biological Screening Assays Include Many Pan-Assay Interference Compounds but Also Candidates for Polypharmacology. , 2016, Journal of medicinal chemistry.
[17] K. Shokat,et al. Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.
[18] J. Bajorath,et al. Compound promiscuity: what can we learn from current data? , 2013, Drug discovery today.
[19] Dimitrios H Roukos,et al. Networks medicine: from reductionism to evidence of complex dynamic biomolecular interactions. , 2011, Pharmacogenomics.
[20] Matthew J. O’Meara,et al. The Recognition of Identical Ligands by Unrelated Proteins. , 2015, ACS chemical biology.
[21] J. Peters,et al. Pharmacological Promiscuity: Dependence on Compound Properties and Target Specificity in a Set of Recent Roche Compounds , 2009, ChemMedChem.
[22] Jürgen Bajorath,et al. Determining the Degree of Promiscuity of Extensively Assayed Compounds , 2016, PloS one.
[23] Jürgen Bajorath,et al. High-resolution view of compound promiscuity , 2013, F1000Research.
[24] J. Thornton,et al. Shape variation in protein binding pockets and their ligands. , 2007, Journal of molecular biology.
[25] J. Irwin,et al. An Aggregation Advisor for Ligand Discovery. , 2015, Journal of medicinal chemistry.
[26] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[27] J. Baell,et al. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.
[28] J. Baell,et al. Chemistry: Chemical con artists foil drug discovery , 2014, Nature.
[29] P. Shannon,et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.
[30] B. Shoichet. Screening in a spirit haunted world. , 2006, Drug discovery today.
[31] P. Nurse,et al. Reductionism: The ends of understanding , 1997, Nature.
[32] G. V. Paolini,et al. Global mapping of pharmacological space , 2006, Nature Biotechnology.